INTRODUCTION
============

T-lymphoblastic leukemia (T-cell acute lymphoblastic leukemia \[T-ALL\]), a highly malignant cancer derived from T-cell progenitors, comprises 15% of acute lymphoblastic leukemia cases \[[@B1], [@B2]\]. T-ALL is a genetically heterogeneous disease with translocations that usually involve recombination between T-cell receptor (*TCR*) loci and several different partner genes \[[@B3]\]. Most of these translocations result in deregulation of the partner genes that are located near *TCR* regulatory elements \[[@B4]\]. The most common partner genes are *HOX11*, *HOX11L2*, *MYC*, and *TAL1*. Consequently, these partner genes, rather than the *TCR*, may play important roles in T-cell leukemogenesis. Translocations involving *TCR* loci are found in about 35% of T-ALL cases, and unidentified partner genes are involved in 5-10% of cases \[[@B5]\]. This report presents a case of T-ALL in which the leukemic cells showed the simultaneous chromosomal abnormalities t(X;14)(q22;q11.2) and t(12;14)(p13;q11.2). To our knowledge, this simultaneous translocation has not been previously reported, and Xq22 has been reported as a partner locus only once in childhood T-ALL \[[@B3]\].

CASE REPORT
===========

A 27-yr-old man was admitted to our hospital complaining of headache, dizziness, nausea, and vomiting, which began 3 days before admission. No palpable lymph-node enlargement or hepatosplenomegaly was detected on physical examination. Laboratory findings were as follows: white blood cell (WBC) count, 49.5×10^9^/L; hemoglobin level, 161 g/L; and platelet count, 36×10^9^/L. A peripheral blood smear showed that 95% of WBCs were blasts ([Fig. 1A](#F1){ref-type="fig"}). The serum lactate dehydrogenase (LDH) level was markedly elevated to 13,022 IU/L. The patient\'s bone marrow was nearly packed with small-to-medium sized leukemic cells with a high nuclear/cytoplasmic ratio, which was calculated as 93.2% ([Fig. 1B, C](#F1){ref-type="fig"}). A biopsy showed hypercellularity with diffuse infiltration of immature blast cells ([Fig. 1D](#F1){ref-type="fig"}). Flow cytometry revealed that the leukemic blasts with intermediate CD45 expression and low side scatter (SSC) were positive for CD2, CD7, CD5, and CD3, and negative for TdT, CD34, CD13, CD33, CD10, CD19, CD20, and CD22. Therefore, the patient was diagnosed with T-ALL.

The patient\'s karyotype was 46,Y,t(X;14)(q22;q11.2),t(12;14)(p13;q11.2) ([Fig. 2](#F2){ref-type="fig"}). FISH analysis was performed to determine the breakpoints using a T-cell receptor alpha delta (TCRAD) DNA Probe, Split Signal (DakoCytomation, Glostrup, Denmark), and it revealed 2 red and 2 green abnormal signal patterns in 89% of the cells, suggesting *TCR* α/δ rearrangements in both chromosomes. To map the Xq22 breakpoint, 2 bacterial artificial chromosome (BAC) clones, RP11-815E21 and RP11-105F23 (Empire Genomics, Buffalo, NY, USA), were used \[[@B3]\], and break-apart signal patterns were obtained, suggesting insulin receptor substrate *(IRS)4* gene translocation ([Fig. 3](#F3){ref-type="fig"}). Additional FISH analyses by using the LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe (Vysis/Abbott Molecular, Des Plaines, IL, USA), the TEL/AML1 ES Dual Color Translocation Probe (Vysis/Abbott Molecular), the LSI p16(9p21)/CEP 9 Dual Color Probe (Vysis/Abbott Molecular), the LSI MLL Dual Color, Break Apart Rearrangement Probe (Vysis/Abbott Molecular), and the LSI MYC Dual Color, Break Apart Rearrangement Probe (Vysis/Abbott Molecular) showed no abnormal signals.

The patient was treated with hyper-CVAD (cyclophosphamide, vincristine, adriamycin, and dexamethasone) as the first course of induction chemotherapy. Complete remission was achieved after 1 month and was confirmed by normal TCRAD FISH signals. At that time, the patient\'s karyotype was 46,XY \[20\]. Next, the patient was treated with high-dose methotrexate/cytarabine (HD MTx/Ara-C) as the first course of consolidation therapy, hyper-CVAD as the second consolidation therapy, and then allogeneic peripheral blood stem cell transplantation (allo-PBSCT) was performed. However, a central nervous system (CNS) relapse was diagnosed 1 yr later, and the patient died of sepsis while receiving induction chemotherapy 1 month after relapse.

DISCUSSION
==========

T-ALL is a malignant proliferation of T-lymphoid blasts, and 50-70% of cases have abnormal karyotypes \[[@B2], [@B6]\]. The chromosomal rearrangements in T-ALL typically involve breakpoints in bands where *TCR* genes are located, including 14q11 (*TCR*-α and *TCR*-δ), 7q32-36 (*TCR*-β), and 7p15 (*TCR*-γ) \[[@B2], [@B7]\]. During V(D)J recombination in T-cell development, several genes transcribed at an early stage of thymocyte development are in an \"open\" chromatin configuration and are vulnerable to the action of recombinases. Consequently, illegitimate recombination may place target partner genes next to *TCR* regulatory sequences. This may lead to their aberrant expression in developing thymocytes, thus leading to T-ALL, with differentiation blocked at various stages of maturation \[[@B5]\]. Commonly involved partner genes of *TCR* loci include the transcription factors *HOX11* (*TLX1*) (10q24), *HOX11L2* (*TLX3*) (5q35), *MYC* (8q24.1), *TAL1* (1p32), *TAL2* (9q32), *LYL1* (19p13), *LMO1* (11p15), and *LMO2* (11p13), and the cytoplasmic tyrosine kinase *LCK* (1p34.3-35) \[[@B6], [@B8]-[@B10]\].

Simultaneous rearrangements targeting *TCR*-β and -α loci are observed in 4% of patients with T-ALL, possibly reflecting a higher susceptibility to errors in V(D)J recombination \[[@B11]\]. In this study, we described a case of T-ALL with simultaneous translocation of both *TCR* α/δ loci (14q11) to different partner loci (Xq22 and 12p13). From a molecular perspective, Xq22 and 12p13 were juxtaposed with the *TCR* α/δ loci (14q11). Breakpoints within the *TCR* α/δ locus occur in more than 20% of T-ALL cases with abnormal karyotypes, and the mechanism underlying these translocations most likely involves illegitimate V(D)J recombination \[[@B4], [@B12], [@B13]\].

In several T-ALL cases, t(12;14)(p13;q11) has been observed in association with the *CCND2* gene, which is thought to stimulate cellular proliferation via cell cycle activation \[[@B1], [@B4]\]. The Xq22 locus is a rare partner gene, and to our knowledge, has been reported only once by Karrman et al. \[[@B3]\] in a pediatric case of T-ALL in which Xq22 was translocated to 7q34 (*TCR*-β). There is no report of adult T-ALL involving the translocation of Xq22 and *TCR* α/δ. The molecular genetic characterization of t(X:7) revealed the *IRS4* gene \[[@B3], [@B14]\].

Although an additional study was not available in our case, FISH using the RP11-815E21 and RP11-105F23 BAC probes (Empire Genomics) at Xq22.3 showed a break-apart signal pattern, suggesting *IRS4* gene translocation. The exact role of *IRS4* remains unclear; however, IRS proteins mediate signaling from insulin and insulin-like growth factor 1 receptors, and have important effects on cell growth and survival \[[@B15]\].

In rarely observed cytogenetic abnormalities, it is difficult to uncover any relationship with prognosis. In a UK-US collaborative group study of 356 adult T-ALL cases, the remission rate was over 90%, and the 5-yr survival rate was approximately 50% \[[@B16]\]. However, considering that in the case reported by Karrman et al. \[[@B3]\] the patient relapsed and died about 2 yr after diagnosis, and the outcome in our case, where the patient relapsed and died about 1 yr after the initial diagnosis, *IRS4* gene involvement may be related to a poor prognosis.

In conclusion, this is the first case report of T-ALL in which both *TCR* α/δ loci (14q11) were translocated simultaneously to different partner loci. One of these partner loci, Xq22, was rare and was found to involve *IRS4*, which may have an important effect on cell growth and survival, and to be associated with a poor prognosis.

No potential conflict of interest relevant to this article was reported.

![T-lymphoblastic leukemia. Peripheral blood smear containing leukemic cells (Wright\'s stain, ×200) (A). Bone marrow aspirate smear showing leukemic cells that are small-to-medium sized, with a high nuclear-to-cytoplasmic ratio (Wright-Giemsa stain, ×200 (B) and ×1,000 (C)). Biopsy section showing hypercellularity with heavy infiltration of immature cells (H&E, ×100) (D).](alm-32-220-g001){#F1}

![Karyotype at diagnosis showing 46,Y,t(X;14)(q22;q11.2),t(12;14)(p13;q11.2). Arrows indicate the rearranged chromosomes.](alm-32-220-g002){#F2}

![FISH at initial diagnosis using the TCRAD DNA Probe, Split Signal (DakoCytomation, Glostrup, Denmark), which showed 2 red and 2 green abnormal signals in metaphase (A) and interphase (B). A schematic diagram of the positions of RP11-815E21 and RP11-105F23 at Xq22.3 (C). Start and end positions were acquired from NCBI36/hg18 assembly. FISH using RP11-815E21 and RP11-105F23 showing 1 red and 1 green break-apart signal (D).\
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